Piperazine derivatives
AssigneePfizer Inc.
InventorsLaura C. Blumberg, Matthew F. Brown, Ronald P. Gladue, Molly A. McGlynn, Christopher S. Poss
Life of this patent
Estimating the term…
Abstract
A compound of the formula or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R1, R2, R3, and R4 are as defined herein and are useful to treat inflammation and other immune disorders.
Claims6
A compound of the formula
- or the pharmaceutically acceptable salt thereof;
- wherein R20 and R2 are as defined below:
- R20 R2 H Me H H H —SO2N(Me)2 Me.
A compound of the formula
- or the pharmaceutically acceptable salt thereof;
- wherein R20 and R2 are as defined below:
- R20 R2 H H H H.
A compound of the formula
- or the pharmaceutically acceptable salt thereof;
- wherein R20 and R2 are as defined below:
- R20 R2 Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me Me.
A compound of the formula
- or the pharmaceutically acceptable salt thereof;
- wherein R20 and R2 are as defined below:
- R20 R2 H —SO2NMe2 Me.
A compound of the formula
- or the pharmaceutically acceptable salt thereof;
- wherein R2 is H and R20 is
- or
A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, comprising an amount of a compound according to any of claims, 1, 2, 3, 4, 5, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.